[go: up one dir, main page]

DK0661060T3 - Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling - Google Patents

Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling

Info

Publication number
DK0661060T3
DK0661060T3 DK94120595T DK94120595T DK0661060T3 DK 0661060 T3 DK0661060 T3 DK 0661060T3 DK 94120595 T DK94120595 T DK 94120595T DK 94120595 T DK94120595 T DK 94120595T DK 0661060 T3 DK0661060 T3 DK 0661060T3
Authority
DK
Denmark
Prior art keywords
preparation
high concentrated
concentrated immunoglobulin
immunoglobulin
highly concentrated
Prior art date
Application number
DK94120595T
Other languages
English (en)
Inventor
Yendra Dr Linnau
Johann Dr Eibl
Wolfgang Dr Teschner
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6506449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0661060(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of DK0661060T3 publication Critical patent/DK0661060T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94120595T 1993-12-28 1994-12-23 Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling DK0661060T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4344824A DE4344824C1 (de) 1993-12-28 1993-12-28 Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
DK0661060T3 true DK0661060T3 (da) 2001-07-30

Family

ID=6506449

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94120595T DK0661060T3 (da) 1993-12-28 1994-12-23 Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling

Country Status (15)

Country Link
US (1) US5608038A (da)
EP (1) EP0661060B1 (da)
JP (1) JP3040678B2 (da)
AT (2) AT407707B (da)
CA (1) CA2138853A1 (da)
CZ (1) CZ284186B6 (da)
DE (2) DE4344824C1 (da)
DK (1) DK0661060T3 (da)
ES (1) ES2158877T3 (da)
FI (1) FI111224B (da)
HR (1) HRP941018B1 (da)
HU (1) HU220766B1 (da)
NO (1) NO315260B1 (da)
RU (1) RU2104713C1 (da)
YU (1) YU77994A (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
DE69810481T2 (de) * 1997-06-13 2003-09-25 Genentech Inc., San Francisco Stabilisierte antikörperformulierung
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
RU2240136C1 (ru) * 2003-04-10 2004-11-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н.Габричевского МЗ РФ" Композиция, содержащая иммуноглобулины и целевые добавки
RU2264229C2 (ru) * 2003-07-28 2005-11-20 Ковшик Игорь Геннадьевич Препарат секреторного иммуноглобулина а, обладающий противовирусным и антибактериальным действием
RU2442571C2 (ru) * 2004-07-23 2012-02-20 Дженентек, Инк. Кристаллизация антител или их фрагментов
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
SI3345615T1 (sl) 2010-03-01 2020-03-31 Bayer Healthcare Llc Optimizirana monoklonska protitelesa proti zaviralcu poti tkivnega faktorja (TFPI)
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
EP3071181B1 (en) 2013-11-18 2021-03-24 Formycon AG Pharmaceutical composition of an anti-vegf antibody
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
JP6716577B2 (ja) 2014-10-01 2020-07-01 イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． 粘度低下物質を含有する、多糖および核酸の調合薬
RU2599029C1 (ru) * 2015-07-16 2016-10-10 Игорь Геннадьевич Ковшик Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
FI3334747T3 (fi) 2015-08-13 2023-11-30 Amgen Inc Antigeenia sitovien proteiinien varattu syväsuodatus
EP3528787A4 (en) 2016-10-21 2020-05-06 Amgen Inc. PHARMACEUTICAL FORMULATIONS AND PROCESSES FOR THEIR PREPARATION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075193A (en) * 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763C (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
EP0168506B2 (en) * 1984-07-07 1998-01-07 Armour Pharma GmbH Process for preparing gamma globulin suitable for intravenous administration
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.

Also Published As

Publication number Publication date
CA2138853A1 (en) 1995-06-29
FI946104A0 (fi) 1994-12-27
FI946104L (fi) 1995-06-29
CZ284186B6 (cs) 1998-09-16
HRP941018B1 (en) 1999-12-31
NO315260B1 (no) 2003-08-11
DE4344824C1 (de) 1995-08-31
HU9403795D0 (en) 1995-02-28
JPH07206709A (ja) 1995-08-08
YU77994A (sh) 1997-03-07
ES2158877T3 (es) 2001-09-16
NO945045D0 (no) 1994-12-27
EP0661060A3 (de) 1997-01-15
DE59409761D1 (de) 2001-06-28
FI111224B (fi) 2003-06-30
EP0661060B1 (de) 2001-05-23
US5608038A (en) 1997-03-04
JP3040678B2 (ja) 2000-05-15
ATA237894A (de) 2000-10-15
EP0661060A2 (de) 1995-07-05
RU2104713C1 (ru) 1998-02-20
ATE201328T1 (de) 2001-06-15
HUT70449A (en) 1995-10-30
CZ328494A3 (en) 1995-07-12
HRP941018A2 (en) 1997-04-30
NO945045L (no) 1995-06-29
HU220766B1 (hu) 2002-05-28
AT407707B (de) 2001-05-25

Similar Documents

Publication Publication Date Title
DK0661060T3 (da) Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling
IS4185A (is) Hliðstæð aðferð til framleiðslu fenýlsúlfonylamino-pýrimidines afleiða
AU5612694A (en) Injectable composition
YU47204B (sh) Derivati didehidro-vitamina d3
ES2118686T3 (es) Extracto estable de hypericum perforatum l., proceso para su preparacion y composiciones farmaceuticas.
FI952797A0 (fi) D-vitamiinianalogin uusi kiteinen muoto
ES2140565T3 (es) Nuevos derivados de pirazina-carboxamida, su preparacion y su utilizacion en medicamentos.
GR3003631T3 (da)
AU5652796A (en) Solid compositions containing polyethyleneoxide and a non-am orphous active principle
ATE121086T1 (de) Sulfonylbenzyl-substituierte benzo- und pyridopyridone.
AU6593094A (en) Fuel additives
ES2082424T3 (es) 1-aminonaftalenos sustituidos y composiciones estabilizadas.
DE59709731D1 (de) Niedrigviskose Polyisocyanatmischung
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
NO20013499D0 (no) Farmasöytisk blanding omfattende en kombinasjon av en profen og andre aktive forbindelser
ES2021334B3 (es) Composiciones de caucho que contienen derivados aminicos del 1,3,4-triadiazol.
KR830010091A (ko) 구연산 나프티드로푸릴의 제조방법
AU1508592A (en) Sweetening agents derived from l-glutamic acid and their method of preparation
BR0208347A (pt) Compostos de antraquinona auto-redutores
DK0713485T3 (da) Thiocarbamoylforbindelser som mikrobicider
KR900018123A (ko) 광학적 활성인 d-2-n-펜아세틸아미노-4-메틸 포스피노부티르산의 라세미화 방법
KR870008535A (ko) "밤"가루(율분)
HUT35652A (en) Process for production of veterinary composition containing sulphamids suitable against illnesses caused by pathogene coli stocks
KR950028765A (ko) 생약 엑스 함유 액제 조성물
KR930003920A (ko) 스테비아계 내복액 및 그 제조방법